Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>US drug regulator approves the use of <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">Remdesivir</keyword> for treating hospitalised COVID-19 patients.</li><li>The US FDA said Veklury (the drug's brand name) cuts the recovery time on average by five days during clinical trials.</li><li>Cipla, Zydus Cadila, Dr Reddy’s are some of the companies that have launched the generic drug Remdesivir in India</li><li>Remdesivir has received much criticism from experts over its effectiveness. A WHO Solidarity trial found that the drug failed to reduce the mortality or hospital stay of the patients.</li></ul>The shares of pharma major Cipla, Zydus Cadila, Jubilant Life Sciences and Dr Reddy Labs gained during the early trading hours on Friday after the US Food and Drug Administration (FDA) approved the use of antiviral drug Remdesivir to treat COVID-19 patients in hospitals. The US FDA has said Veklury (drug's brand name) cut the recovery time on average by five days during clinical trials. "Veklury is the first treatment for COVID-19 to receive FDA approval," the FDA said in a statement. The Remdesivir boost <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Share price change on Oct 23* </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Share price change since June 30 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">21.20% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">28% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">20% </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jubilant Life Sciences </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2% </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">14% </td></tr></tbody></table>*Share price change on Oct 23 till 10:35 am USFDA has approved the use of the drug for treatment of hospitalised COVID-19 patients — for adults and paediatric patients (12 years of age and older) and weighing at least 40 kilograms. The drug regulator’s decision was supported by the analysis of data from "three randomised, controlled clinical trials that included patients hospitalised with mild-to-severe Covid-19". Cipla, Zydus Cadila and Dr Reddy Laboratories are among the top drugmakers that have bagged the contract for the <a href="https://www.businessinsider.in/science/health/news/these-are-the-companies-that-are-making-remdesivir-in-india/articleshow/78030739.cms">manufacturing of Remdesivir in India</a>. These are the remdesivir drug manufacturers in India: <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5400 </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4000 </td></tr></tbody></table> However not all experts are convinced of Remdesivir’s ‘effectiveness’ The Remdesivir COVID-19 vaccine has received much criticism from experts over its effectiveness. Even a WHO Solidarity trial examined the effects of remdesivir, and three other treatment candidates in more than 11,000 patients in 30 countries and the results from the clinical trial found that none of the drugs “substantially affected mortality,” reduced the need to ventilate patients or shortened hospital stays. “These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay,” the<a href="https://www.businessinsider.in/science/health/news/remdesivir-the-only-antiviral-authorized-for-covid-19-in-us-does-not-improve-chances-of-survival-a-massive-who-study-found/articleshow/78699732.cms"> report said</a>. SEE ALSO: <a href="https://www.businessinsider.in/india/news/trump-calls-india-china-and-russia-filthy-while-justifying-exit-from-paris-agreement/articleshow/78821267.cms" data-type="tilCustomLink">Trump calls India, China and Russia ‘filthy’ while justifying exit from Paris Agreement</a> <a href="https://www.businessinsider.in/science/health/news/gileads-remdesivir-just-got-the-first-fda-approval-to-be-used-as-a-treatment-for-coronavirus-patients/articleshow/78818920.cms" data-type="tilCustomLink">Gilead's remdesivir just got the first FDA approval to be used as a treatment for coronavirus patients</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-cipla-zydus-cadila-dr-reddy-laboratories-tech-mahindra-avenue-supermarts-cochin-shipyard-and-others/articleshow/78820314.cms" data-type="tilCustomLink">Top stocks to watch — Cipla, Zydus Cadila, Dr Reddy Laboratories, Tech Mahindra, Avenue Supermarts, Cochin Shipyard, and others</a>

Cipla, Zydus Cadila, Jubilant Life and Dr Reddy’s shares gain after FDA approves Remdesivir for treating COVID-19 patients

<ul><li>Dr. Reddy’s Laboratories <a href="https://timesofindia.indiatimes.com/business/india-business/dr-reddys-launches-remdesivir-to-treat-covid-19-in-india/articleshow/78015814.cms">launched</a> generic drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">Remdesivir</keyword> under the brand name Redyx in India on September 9. </li><li>Redyx will be available in the market for ₹5,400 per 100 mg vial. </li><li><keyword id="72130" type="COMPANY" weightage="20" keywordseo="Zydus-Cadila">Zydus Cadila</keyword>, on August 13, launched the cheapest version of Remdesivir under the brand name Remdac. </li><li>Apart from <keyword id="6357157" type="UNKNOWN" weightage="20" keywordseo="cipla">Cipla</keyword> and <keyword id="1167725" type="PERSON" weightage="20" keywordseo="Hetero-Labs">Hetero Labs</keyword>, Jubilant Lifesciences and Mylan are working to manufacture the drug in India. </li></ul>Dr Reddy’s Laboratories has <a href="https://timesofindia.indiatimes.com/business/india-business/dr-reddys-launches-remdesivir-to-treat-covid-19-in-india/articleshow/78015814.cms">launched</a> the generic drug Remdesivir under the brand name Redyx in India. Remdesivir used to treat patients suffering from severe symptoms of COVID-19. Redyx will be available in the market for ₹5,400 per 100 mg vials. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Redyx </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹4000</td></tr></tbody></table> Dr Reddy’s Lab is the sixth pharmaceutical company to introduce Remdesivir in India. On August 13, Zydus Cadila launched its own version of Remdesivir called Remda in the Indian market. Remdac is priced at ₹2,800 per 100 mg vial, making it the cheapest version of the drug so far. Zydus Cadila said that the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients. In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19. Previously, pharmaceutical giants Cipla and Hetero introduced generic versions Remdesivir — an antiviral drug first used to treat Ebola — to fight coronavirus. The drug was launched in India in July. India’s Health Ministry approved use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairment, pregnant and lactating women, children below 12 years age. Hetero said it will make its version of Remdesivir — Covifor — available between ₹5,000 to ₹6,000 for a vial. Whereas, Cipla's Cipremi is available for ₹4000 for per 100 mg vial. Cipla’s Cipremi is available for only those patients who are on oxygen support. Apart from Cipla and Hetero Labs, Jubilant Lifesciences and Mylan are also working to manufacture the drug in India. Dr Reddy’s Laboratories, Biocon firm Syngene and has also received voluntary permission from Gilead Sciences to produce Remdesivir in India. (With inputs from PTI) SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/why-the-latest-surge-in-covid-19-infections-in-india-may-cause-more-deaths/articleshow/78011731.cms">What India’s rising COVID-19 infections don’t⁠ reveal — the lack of health infrastructure in remote areas</a>

These are the companies that are making Remdesivir in India

<ul><li>Zydus Cadila, on August 13, launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19. </li><li>Priced at ₹2,800 per 100 mg vial, it is the cheapest <keyword id="9013152" type="UNKNOWN" weightage="20" keywordseo="remdesivir-drug">Remdesivir drug</keyword> available in India </li><li>Apart from Cipla and Hetero Labs, Jubilant Lifesciences, and Mylan are working to manufacture the drug in India. </li></ul>Zydus Cadila has launched Remdesivir under the brand name Remdac, used to treat patients suffering from severe symptoms of COVID-19, in the Indian market. Remdac is priced at ₹2,800 per 100 mg vial, making it the cheapest version of the drug so far. Zydus Cadila is the fifth company to make this antiviral drug in India. They have said that the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients. <table style="border-width: initial; border-style: none; width: 468pt; table-layout: fixed;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brand </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdesivir Price </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Cadila </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Remdac </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹2800 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hetero Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Covifor </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹5000-₹6000 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipremi </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Not disclosed yet </td></tr></tbody></table> In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences Inc to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19. Previously, pharmaceutical giants Cipla and Hetero introduced generic versions Remdesivir — an antiviral drug first used to treat Ebola — to fight coronavirus. India’s Health Ministry approved use of the drug to treat mild cases of coronavirus. However, the drug is not recommended to treat those who have several renal impairment, pregnant and lactating women, children below 12 years age. Hetero said it will make its version of Remdesivir — Covifor — available between ₹5,000 to ₹6,000 for a vial. Whereas, Cipla is yet to decide the cost of Cipremi. Cipla’s Cipremi is available for only those patients who are on oxygen support. Apart from Cipla and Hetero Labs, Jubilant Lifesciences and Mylan are also working to manufacture the drug in India. Dr Reddy’s Laboratories, Biocon firm Syngene and has also received voluntary permission from Gilead Sciences to produce Remdesivir in India. (With inputs from PTI) SEE ALSO: <a href="https://www.businessinsider.in/politics/world/news/trump-was-rushed-from-the-briefing-room-by-secret-service-after-a-shooting-outside-of-the-white-house/articleshow/77474005.cms">Trump was rushed from the briefing room by Secret Service after a shooting outside the White House</a> <a href="https://www.businessinsider.in/careers/news/mckinsey-facebook-amazon-nokia-and-some-other-companies-looking-for-a-product-manager-right-now/slidelist/77464438.cms">McKinsey, Facebook, Amazon, Nokia — and some other companies looking for a product manager right now</a> <a href="https://www.businessinsider.in/business/startups/news/how-karan-bajaj-sold-his-less-than-18-month-old-startup-white-hat-jr-to-byjus/articleshow/77415329.cms">A WhatsApp message, six weeks of talks and a $300 million deal – how Karan Bajaj sold his less than 18-month old startup White Hat Jr to Byju’s</a>

<ul><li>Cipla will launch its version of Remdesivir in the next 1-2 days under the brand name 'Cipremi'.</li><li>The drug will be sold at an approximate price of ₹4,000 per vial.</li><li>Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug demonstrated faster clinical recovery in hospitalised patients.</li><li>The Union Health Ministry has asked all the states to strengthen their vigil, so that black marketing of Covid-19 drug Remdesivir is prevented.</li></ul>As India faces a shortage of Covid-19 drug Remdesivir, the pharmaceutical company Cipla said it will launch its version of Remdesivir in the next 1-2 days. <a href="https://www.cnbctv18.com/healthcare/exclusive-as-india-faces-shortage-of-remdesivir-cipla-says-its-supplies-will-hit-market-in-next-1-2-days-6281911.htm">In an interview with CNBC TV18</a>, Kedar Upadhyay, Cipla’s CFO said that the Daman-based Sovereign Pharma had released the first batch of the drug from its manufacturing plant and Cipla will be selling it under the brand name 'Cipremi'. While Mumbai-based BDR Pharma holds the contract for manufacturing of Cipla’s Remdesivir, the company has further sub-contracted the manufacturing of the finished dosage and packaging to Daman-based Sovereign Pharma. <div type="Article" hostid="261" msid="76747405" title="These are the companies manufacturing COVID-19 drug Remdesivir in India" mstype="2" mssubtype="0"></div> "We are attempting to launch Remdesivir in the next 1-2 days. We cannot comment on the volumes just as yet, but there is a huge demand-supply gap in the market," Upadhyay told CNBC TV18. However, <a href="https://www.cnbctv18.com/healthcare/exclusive-as-india-faces-shortage-of-remdesivir-cipla-says-its-supplies-will-hit-market-in-next-1-2-days-6281911.htm">reports</a> say that Sovereign Pharma has the capacity to scale up production to 95,000 vials per month. Sovereign Pharma got all necessary approvals for manufacturing the drug within a week, after an inspection by the Central Drugs Standard Control Organisation. The drug will be sold at an approximate price of ₹4,000 per vial. Upadhyay told CNBC that the company is also preparing to set up a Remdesivir manufacturing facility in-house. Remdesivir is considered a key drug in the fight against Covid-19. The drug’s popularity grew after a randomised clinical trial used the drug on 1,063 patients over 60 centres across US, Europe and Asia and saw faster clinical recovery in hospitalised patients. To expand the supply of Remdesivir, US-based Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan. The agreements allow Cipla and other companies including Dr. Reddy's Laboratories Ltd.; Hetero Labs Ltd.; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. to manufacture Remdesivir for distribution in 127 countries. Government cracks down on Remdesivir black market The Union Health Ministry has asked all the states to take all measures to ensure that Remdesivir is not sold in the black market. The ministry acted upon it after t<a href="https://www.outlookindia.com/newsscroll/health-ministry-steps-in-to-curb-black-marketing-of-covid-drug/1888995">he Directorate General of Health Services said that it has received </a>a letter from LocalCircles routed through the Health Ministry, raising concerns over black marketing and overpricing of Remdesivir in certain markets. "In view of the above, you are requested to instruct your enforcement officials to keep strict vigil on the matter to prevent black marketing and sale of Remdesivir injection above the MRP," the DGHS said in the letter to the states. SEE ALSO: <a href="https://www.businessinsider.in/science/news/the-us-bought-up-90-of-the-worlds-supply-of-remdesivir-for-the-next-3-months-and-patents-mean-many-countries-wont-be-able-to-get-any/articleshow/76729248.cms" data-type="tilCustomLink">The US bought up 90% of the world's supply of remdesivir for the next 3 months, and patents mean many countries won't be able to get any</a> <a href="https://www.businessinsider.in/stock-market/news/gilead-rises-after-pricing-its-coronavirus-fighting-drug-remdesivir/articleshow/76692239.cms" data-type="tilCustomLink">Gilead rises after pricing its coronavirus-fighting drug remdesivir</a>

Cipla says COVID-19 drug Remdesivir will hit market this week

New Delhi, Jun 23 () Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday. "In line with our overall philosophy of driving access and affordability, the drug will be priced at less than Rs 5,000 per vial vial for injection 100 mg -- amongst the lowest pricing for remdesivir globally," Cipla said in an e-mailed response to . On being asked about the launch of the drug, the company said: "We have started commercial manufacturing, and the product will be available in the next 8-10 days." Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose. Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection. Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said on Sunday. In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir. According to the Union health ministry update, the total number of COVID-19 cases in the country stood at 4,40,215 on Tuesday and the death toll was at 14,011. AKT HRS

Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial

<ul><li>The <keyword id="6354458" type="UNKNOWN" weightage="20" keywordseo="US">US</keyword> Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September.</li><li>This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials.</li></ul> The Donald Trump administration has secured nearly the entire world stock of antiviral drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">remdesivir</keyword> from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key Covid-19 drug for the rest of the world. As a result of an agreement with the drug maker announced earlier this week, the US Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials, the US Health and Human Services said. The agreement allows hospitals in the US to purchase the drug in amounts allocated by HHS and state health departments. Hospitals in the US will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," US Health and Human Services Secretary Alex Azar said in a statement. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people." Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. To expand supply of remdesivir, Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan The agreements allow the companies -- Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. -- to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country is subject to local laws and regulations. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier.

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

<ul class="summary-list"><li>The US government is on pace to run out of <a href="https://www.businessinsider.com/coronavirus-treatment-gileads-remdesivir-clinical-testing-timeline-2020-3">remdesivir</a> drugs at the end of June and does not know when it will get more.</li><li>The Department of <keyword id="172137" type="ORGANIZATION" weightage="60" keywordseo="Health-and-Human-Services">Health and Human Services</keyword> <a href="https://edition.cnn.com/2020/06/07/health/remdesivir-donation-runs-out-coronavirus/index.html">told CNN</a> that <keyword id="195727" type="COMPANY" weightage="60" keywordseo="Gilead">Gilead</keyword>, which makes the drug, will ship a final batch on the week of June 29.</li><li>"We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Dr. Robert Kadlec told the network.</li><li><keyword id="8775508" type="UNKNOWN" weightage="60" keywordseo="remdesivir">Remdesivir</keyword> is the only widely approved COVID-19 treatment, and <a href="https://www.businessinsider.com/remdesivir-study-positive-results-hospitalized-coronavirus-patients-2020-5">early studies found</a> it helped mitigate the effect of the virus.</li><li>All 1.5 million vials of remdesivir that Gilead has in stock are in circulation. Gilead says it will get new stocks of crucial raw materials to make more in July.</li></ul>The US supply of the COVID-19 treatment <a href="https://www.businessinsider.com/coronavirus-treatment-gileads-remdesivir-clinical-testing-timeline-2020-3">remdesivir</a> is on pace to run out at the end of June, the Department of Health and Human Services has said.Dr. Robert Kadlec, an <keyword id="333946" type="ORGANIZATION" weightage="60" keywordseo="HHS">HHS</keyword> official, <a href="https://edition.cnn.com/2020/06/07/health/remdesivir-donation-runs-out-coronavirus/index.html">told CNN</a> that <a href="https://www.businessinsider.com/gilead-history-making-antiviral-treatments-from-hiv-to-coronavirus-2020-5">Gilead Sciences</a>, which created the drug, is scheduled to send the government a final shipment the week of June 29, but after that the HHS does not know when it will get more."We're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said.The US government <a href="https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html">received 607,000</a> vials of the drug in early May, which it planned to use over six weeks on 78,000 patients in the worst-hit states.Gilead has so far donated 1.5 million vials of the drug worldwide. That is all it has in stock so far.<div type="image" title="FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake" height="2406" width="4812" msid="76260855" hostid="261"></div>It is uncertain when the US will be able to get more after the final batch runs out.Gilead <a href="https://www.wsj.com/articles/u-s-distribution-of-covid-19-drug-remdesivir-improved-but-still-wasnt-enough-11591349401">says</a> it will be able to produce more remdesivir starting in July, when the raw materials needed to make the drug — which it had ordered in January — are expected to arrive.The US Food and Drug Administration hurriedly <a href="https://www.businessinsider.com/gilead-remdesivir-emergency-fda-authorization-coronavirus-2020-5">approved remdesivir as a coronavirus treatment on May 1,</a> and preliminary studies indicate <a href="https://www.businessinsider.com/remdesivir-study-positive-results-hospitalized-coronavirus-patients-2020-5">it has a marked impact on the health of those infected</a>.Scientists found that the benefits appeared much greater for those with less severe symptoms, however, and aren't sure whether it can reduce <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> deaths, <a href="https://www.businessinsider.com/remdesivir-study-positive-results-hospitalized-coronavirus-patients-2020-5">STAT reported</a>.The drug was first manufactured in 2009 to treat victims of the Ebola outbreak but was unsuccessful.It is clear that there is a shortage of the drug in the US. An <a href="https://www.wsj.com/articles/u-s-distribution-of-covid-19-drug-remdesivir-improved-but-still-wasnt-enough-11591349401">investigation by The Wall Street Journal</a>, published last Friday, found that the number of US patients requiring the drug outnumbered available supplies by two to one.<div type="image" title="Daniel O'Day Gilead remdesivir" height="1712" width="3423" msid="76260860" hostid="261"></div>"There's definitely not enough drug for the number of patients who we currently have and probably will have through August, when we may get more drug from Gilead," Michael Ison, a professor of medicine at Northwestern University, told The Journal.The drug, which is administered intravenously, is the leading hope for an approved COVID-19 treatment.Remdesivir has been approved for use on coronavirus patients in the UK, India, Taiwan, and Japan, and regulators in Australia <a href="https://www.theguardian.com/world/2020/jun/05/remdesivir-ebola-drug-endorsed-as-a-coronavirus-treatment-in-australia">are evaluating the drug</a>.Gilead is yet to put a price tag on remdesivir, but the drug could generate $7 billion in sales by 2022, <a href="https://www.reuters.com/article/us-health-coronavirus-remdesivir-idUSKBN23A2MN?taid=5ed82595b0a59e0001b61c6f&amp;utm_campaign=trueAnthem:+Trending+Content&amp;utm_medium=trueAnthem&amp;utm_source=twitterurce=twitter">the investment bank SVB Leerink said last week</a>.An alternative treatment, <a href="https://www.businessinsider.com/category/hydroxychloroquine">hydroxychloroquine</a>, is another option under consideration and <a href="https://www.businessinsider.com/president-trump-says-hes-been-taking-hydroxychloroquine-2020-5?r=US&amp;IR=TIR=T">has been touted by President Donald Trump</a>. The drug has FDA approval to treat malaria but <a href="https://www.businessinsider.com/who-temporarily-suspends-hydroxychloroquine-covid-19-trials-2020-5">has yet to be proved safe or effective</a> as a coronavirus treatment.

The US government's supply of remdesivir — the only drug proved to treat the coronavirus — is due to run out at the end of June

<ul class="summary-list"><li>A variant of <keyword id="8775508" type="UNKNOWN" weightage="60" keywordseo="remdesivir">remdesivir</keyword>, one of the most promising treatments for <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword>, has for more than a year been sold as a treatment for sick cats via a black market connected to big Facebook groups.</li><li>The drug, called <keyword id="9365602" type="UNKNOWN" weightage="60" keywordseo="gs-441524">GS-441524</keyword>, is being sold as a purported cure for Feline Infectious Peritonitis, which is caused by a <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword>, the same family of pathogen that causes COVID-19 in humans. </li><li>Despite not being licensed as a treatment for <keyword id="759794" type="ORGANIZATION" weightage="60" keywordseo="fip">FIP</keyword> by the Food and Drugs Administration, the drug is being sold to US consumers by Chinese firms, with courses sold for up to $10,000.</li><li>The transactions do not take place on Facebook's platform, but large cat owner groups have banded together to connect buyers to sellers, and attempt to screen the drug for purity.</li><li>An academic who pioneered using the drug on cats says that a black market is the only option because pharma giant Gilead, which has the rights to GS, will not license it for use in cats.</li><li>Critics say the unlicensed trade can lead to dangerous, low-quality drugs which could even find their way into human use.</li></ul>As the world seeks a way out the coronavirus crisis, there are hopes that the drug remdesivir may provide part of the solution.The drug is already being used on seriously ill patients after being fast-tracked by medical authorities in the US, though <a href="https://edition.cnn.com/2020/06/07/health/remdesivir-donation-runs-out-coronavirus/index.html">supplies are limited</a> and it may be some time before it becomes more widely available. Business Insider can reveal that a black-market version of the drug, known as GS, is already being used by pet owners to treat a rare but deadly disease suffered by cats.Unlicensed doses of GS — sold in liquid form and distributed in vials — are available through an extensive network of online vendors in China created to serve worried pet owners.<div type="image" title="Remdesivir2 by Getty Images" height="768" width="1024" msid="76260293" hostid="261"></div>Thousands of owners with sick cats have banded together in closed Facebook groups, which connect buyers and sellers, and make efforts to screen shipments for purity.Though no money is exchanged via Facebook, the network acts as a conduit through which people can access the unlicensed drug. A Facebook spokesperson directed Business Insider to the site's policies, which ban the sale of illegal or prescription drugs on the platform, and encourage users to report drug sales. It also said it is using automated technology to scan and identify instances. Business Insider has seen price lists from vendors of the drug suggesting that it is being sold for as much as $10,000 a course, and sent to the US under the guise of a dietary supplement.Some people have also tried to buy it as a backstreet coronavirus remedy for human use, but it is not clear how widespread this is.The cat disease in question is Feline Infectious Peritonitis (FIP). Cats with FIP suffer fever, weight loss and breathing difficulties, and nearly always die.It's caused by a type of a coronavirus — the same family of pathogen that causes COVID-19 in humans. Though they are genetically related, the FIP coronavirus does not cause COVID-19, and vice-versa.The drug being used to treat it is GS-441524, or GS for short. It is being marketed and sold by companies based in China, which ship it to the US.Emeritus Professor Niels Pedersen, a veterinary <keyword id="41551" type="ENTERTAINMENT" weightage="60" keywordseo="science">science</keyword> expert at University of California Davis, says he personally pioneered its use on cats.Pedersen reluctantly supports cat owners seeking to administer the drug to their pets, since there is no legal way to acquire the drug. He told Business Insider that FIP is "now 80% or more curable" with GS.Professor Margaret Hosie, an FIP researcher at the University of Glasgow, told Business Insider that she too had heard anecdotal reports of GS being effective. The closed Facebook groups are also full of stories of GS working.But the Food and Drugs Administration told Business Insider it has not licensed GS-441524 as a treatment for FIP, <a href="https://www.fda.gov/drugs/enforcement-activities-fda/unapproved-drugs">which means it is illegal to sell it as such in the US</a>.Some sites market it instead as a human dietary supplement, Pedersen said, which allows it to be shipped to the US.One campaigner, Anna Mitchell, who has spent a year investigating the GS black market, has called for it to be closed down. Mitchell started to investigate after her own cat got FIP, she told Business Insider."However the injections, the web of lies [about the effectiveness of the drug] and the misinformation is rampant," she said."And I am also worried that pretty soon the model we are seeing develop could spread to [unlicensed treatments for] other feline diseases and also human diseases."Oksana Pyzik, a senior teaching fellow in the School of Pharmacy at University College London, is an expert on the illegal pharmaceuticals market. She told Business Insider that the batches of GS being produced in China could be dangerous."Any medicine that has not been properly investigated for its quality means that we don't know what is inside, whether it is contaminated, whether it has any of the active pharmaceutical ingredients it claims to have," she said.<h2>In Facebook groups, desperate pet owners speak of a "miracle cure" </h2><div type="image" title="Cat2 by Getty Images" height="1500" width="2000" msid="76260297" hostid="261"></div>Facebook groups with thousands of members have have developed in response to the spread of FIP. In the groups, members exchange support and advice on how to treat cats with the disease — and stories of what they claim are the amazing curative powers of GS.Members speak often of <a href="https://www.google.com/search?q=pedersen+study+FIP&amp;rlz=1C5CHFA_enGB838GB838&amp;oq=pedersen+study+FIP&amp;aqs=chrome..69i57.4745j0j8&amp;sourceid=chrome&amp;ie=UTF-8=chrome&amp;ie=UTF-8">a promising February 2019 field study</a> by Pedersen, the UC Davis professor.A field study is a collection of information outside a lab setting. In Pedersen's study he dosed 31 cats suffering FIP with GS. 25 survived and recovered. Robin Kintz, who started the 23,000-member group FIP Warriors, told Business Insider: "When my kitten Henry was diagnosed in February of 2019, I searched the internet for answers and solutions."I came across Dr. Pedersen's research using GS-441525 and then went onto Facebook searching for sources of this miracle drug."GS-441525 was used in clinical trials on humans while the Ebola outbreak was raging in 2012. However, the trials failed.After this, Pedersen began experimenting to see if GS could work on animals, he told Business Insider. In an email, he said that GS and remdesivir are very similar, a conclusion <a href="https://www.sciencedirect.com/science/article/pii/S2352771420300380#!">backed by other researchers</a>.Pedersen said that he asked permission to legally make GS for cats, but was rejected by Gilead, the pharmaceuticals firm that owns the rights to it.Pedersen claims that Gilead is worried that allowing GS to be used on cats would harm its ability to profit from its use in humans. The company did not respond to several requests to comment. Pedersen said that desperate pet owners have been driven to the black market as a result.He is convinced the drug works, and claims that 10,000 cats worldwide have been treated for FIP using GS thanks to his research."This disease, which is virtually always fatal and accounts for 0.3-1.3% of all deaths of cats in the world, is now 80% or more curable with GS-441524," he said.Pedersen also referred to an earlier statement where he defended helping the black market groups.He wrote: "I will continue to provide as much advice as possible for owners and veterinarians using and contemplating the use of black-market GS and GC to treat cats with FIP."He told Business Insider that his veterinary oath compelled him to help pet owners administer the treatment. The statement continued: "I must make it clear that I would have preferred these drugs to be approved and commercialized in the normal manner. I am certain that this will happen within the next few years, and as it does, the black market demand for drugs like GS and GC will wane."<h2>Sold online for as much as $10,000 </h2>But Mitchell, the anti-black market campaigner, says that the support Pedersen has offered to individuals administering illegal GS has encouraged a potentially dangerous black market. "It ballooned in Facebook groups — specifically one that has become gigantic and is really the supply route between the manufacturers and their buyers in the US," she said.The cost of a course of treatment can come to about $10,000. The screenshot below shows the price for a course of 29 bottles, which Mitchell told Business Insider is the amount an owner might want to obtain to treat a serious FIP case.In messages posted inside a Facebook FIP group, cat owners spoke of similar prices.<div type="image" title="cat drug screenshot border" height="530" width="1482" msid="76260301" hostid="261"></div>Mitchell said: "I am surprised by how many people, even those without the money, find a way to acquire that drug, they will go into debt, they will do anything to save their cat. It is a huge, huge market."She said some owners report worrying side effects in their pets, including open sores and wounds from the injections. Other cats are said to relapse after seeing symptoms briefly improve. Kintz, the group administrator, said that some pets experience negative side-effects, but that the group makes efforts to screen batches for purity."Lesions and painful injections are the two most common side effects of the medication. Some sores are worse than others but all resolve with time," said Kintz."Early on when this group was formed, we were able to have several different 'brands' of GS vials tested in a reputable university lab and the results confirmed the biological activity of the GS," she said.Kintz also said the group asks for free batches from suppliers to give to owners who cannot afford the drug."They use the vials as a mini field trial. If the kitties get better, we know it is working."<h2>Humans who believe GS might be a coronavirus treatment seek it out in Facebook cat groups </h2>Recent clinical trials for remdesivir as a treatment for COVID-19 have been so encouraging that Gilead recently signed an agreement with several firms in India and Pakistan to increase production of the drug. However, a form of the drug is still not expected to be widely available on the legitimate market for many months.Pyzik, the pharmaceuticals expert, expressed concern that people pursuing a treatment for COVID-19 could seek out unlicensed forms on the black market. "It is incredibly serious to take a medicine when we don't understand the full nature of its effects in someone that has a coronavirus infection."Again, premature use can lead to a whole series of very serious side effects that can have long lasting disabilities for a person in the future," she said. Kintz said that some had inquired through her group about getting GS to treat COVID-19. "One or two people have reached [out] wanting to get GS for the human coronavirus but we have not gotten involved with that at all," she wrote.

People are paying as much as $10,000 for an unlicensed remdesivir variant for their cats, in a thriving black market linked to Facebook groups

<ul><li>Sensex on Friday opened on a positive note, with a healthy buying in healthcare, capital goods and energy stocks. </li><li>Nifty50 was trading nearly 51.10 points higher or 0.45% from its previous close.</li><li>Here’s a list of stocks buzzing on D-street today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock market opened on a positive note on Friday with the BSE Sensex surpassing the 38,500-mark during the initial trade. Healthy buying was witnessed in healthcare, capital goods and energy stocks. Nifty50 was trading nearly 51.10 points higher or 0.45% from its previous close. These are the <keyword id="35164" type="PERSON" weightage="20" keywordseo="top-stocks">top stocks</keyword> that are buzzing the D-street today. IndiGo’s parent Interglobe Aviation shares trading over 2% lower during the morning trade The overall domestic air passenger traffic declined 83% to 21 lakh passengers in July. This led to domestic carrier Indigo’s shares coming under pressure. IndiGo’s passenger load factor in July was almost flat at 60.2%. However, its market share in July was up at 60.4% compared to 52.8% in June. Shares of its rival airline SpiceJet, was trading flat during the morning session. Hero MotoCorp declined nearly two per cent during the morning trade Shares of the country’s largest two-wheeler maker Hero was trading nearly 2% lower after the company posted a 95.38% decline in consolidated net profit at ₹57.78 crore for the first quarter ended June 30. The total income during the quarter under review declined to ₹3,119.22 crore as compared with ₹8,410.41 crore in the year-ago period. Eicher Motors declines 3% during the morning trade After reporting a consolidated net loss of ₹55 crore for the first quarter ended June 30, the shares of Eicher Motors were trading nearly 3% lower during the early trade. Bank of India trades nearly 2% lower The <keyword id="1922421" type="PERSON" weightage="20" keywordseo="Bank-of-India-shares">Bank of India shares</keyword> were trading nearly 2% lower after the board approved raising up to ₹8,000 crore by preferential issue, QIP, further public offer, etc. Cipla gains over 3% during the morning trade Cipla shares gain over 3% led by a rally in pharma stocks. Cipla is one of the companies in India manufacturing the antiviral drug Remdesivir. Glenmark Pharmaceuticals gains over 3% during the morning trade Shares of Glenmark Pharma was trading nearly 3% higher ahead of first quarter earnings due later today. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/stocks-to-watch-indigo-spicejet-hero-motocorp-bpcl-tata-steel-glenmark-pharma-eicher-motors-bank-of-india-hindalco/articleshow/77536933.cms" data-type="tilCustomLink">Top stocks to watch today—IndiGo, SpiceJet, Hero MotoCorp, BPCL, Tata Steel, Glenmark Pharma and others</a> <a href="https://www.businessinsider.in/business/auto/news/eicher-motors-registers-first-ever-net-loss-of-55-crores-in-at-least-a-decade/articleshow/77526012.cms" data-type="tilCustomLink">Eicher Motors registers first-ever net loss of ₹55 crore in at least a decade</a>

You Searched For "remdesivir price in india" and got 9 results

Cipla, Zydus Cadila, Jubilant Life and Dr Reddy’s shares gain after FDA approves Remdesivir for treating COVID-19 patients

Navdeep Yadav

These are the companies that are making Remdesivir in India

BI India Bureau

These are the companies that are making Remdesivir in India

BI India Bureau

Cipla says COVID-19 drug Remdesivir will hit market this week

Navdeep Yadav

Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial

PTI

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

IANS

The US government's supply of remdesivir — the only drug proved to treat the coronavirus — is due to run out at the end of June

Bill Bostock

People are paying as much as $10,000 for an unlicensed remdesivir variant for their cats, in a thriving black market linked to Facebook groups

Tom Porter

Top stock movers on Dalal Street today — IndiGo, Cipla, Hero MotoCorp, Glenmark Pharma and others

Navdeep Yadav

Popular Keywords

Buying Guides